Microbiome Drug Development Summit Paris

Monday  29 January  2018  8:00 AM    Thursday  1 February  2018 5:59 PM
Save Saved
Last update 02/02/2018
  140

Accelerate the Translation of the Human Microbiome into Safe, Effective and Commercially Scalable Therapeutic Products
CLICK HERE TO FIND OUT MORE

Part of the Microbiome Movement Series, the Microbiome Drug Development Summit Europe kick starts 2018 to help large pharma, biotech and academic institutions accelerate the discovery and clinical development of safe, effective and commercially scalable microbiome-based therapeutics across a broad spectrum of disease indications.

Set to tackle the greatest scientific, regulatory, clinical, manufacturing and commercialization challenges across the entire microbiome-drug development value chain, MDDS Europe will help reveal the applicability of microbiome understanding to develop new therapeutics.

 “The MDD Summit was a great opportunity to meet some of the brightest minds and leading entrepreneurs in the industry. A key event for anyone intending to translate microbiome science into impactful products for patients.”  - Johan van Hylckama Vlieg, VP Microbiome & Human Health Innovation, Chr. Hansen
Previous Attendee, Microbiome Drug Development Summit, Paris 2017 

 

Why We’re Excited for Microbiome Drug Development Summit Europe:

Over 35+ speakers from the forefront of translational microbiome research: 
Learn, share and collaborate with organizations using novel drug modalities including Seres Therapeutics, Vedanta Biosciences, Rebiotix, Enterome, 4D Pharma, Gusto Global, AstraZeneca, Janssen R&D, GSK, Merck, Pfizer and many more

Definitive focus on end-to-end microbiome based drug development: 
Our agenda is carefully positioned so from start to finish, we will integrate leading industry insight to tackle the greatest challenges across the entire drug development value chain

Understand Regulatory Uncertainty in Europe:
With no clear narrative from regulatory agencies, get unique insight into how industry are defining novel regulatory pathways to standardize practice and accelerate speed to market

Overcome Key Clinical Implementation Considerations:
As the microbiome industry accelerates to market approval, learn how companies are selecting accurate patient populations, dosing schedules and clear clinical endpoints to establish safe and effective human trials

Learn to Scale Microbiome Therapeutics with CMC/Manufacturing considerations:
Learn how key companies developing microbiome-based therapeutics are manufacturing to maximize consistency, effectively scale up and improve reliability

Subtractive Therapies and the Microbiome:
Discover how researchers are using subtractive approaches to target narrow-spectrum bacteria through phage development

Exclusive Post-Conference Focus Day – Immuno Oncology and the Human Microbiome:
Join this interactive day to learn from industry how modulation of the microbiota may be used to enhance clinical response rates for patients treated with IO therapeutics

To learn more about Microbiome Drug Development Summit (Paris, 29 January -01 February) and find out how leading researchers are addressing unique scientific and product developmental challenges when bringing a new age of microbiome-based therapeutics, take a look at the event guide.

trade shows business workshop technology Start Up
Nearby hotels and apartments
Boulevard Gouvion-Saint-Cyr 62, Paris, 75017, Île-de-France, France
Boulevard Gouvion-Saint-Cyr 62, Paris, 75017, Île-de-France, France